Cancer Genetics, Inc. and Mendel.ai Announce Strategic Partnership Enabling Artificial Intelligence in Precision Medicine to Drive Personalized Treatment and Accelerate Clinical Trial Matching for Cancer Care

Published on: Monday, April 3rd, 2017 View all Media

  • Powerful New Capability Leverages Artificial Intelligence & Big Data Analytics to Accelerate and Democratize Access to Clinical Trials for Cancer
  • CGI and Mendel.ai will be Among the First in Laboratory Medicine to Provide Real Time, Constant Clinical Trial Matching That Integrates Biomarker and Genomic Data with Electronic Health Records, and Clinical Observations

RUTHERFORD, N.J. & SAN FRANCISCO, C.A., April 3, 2017 (GLOBE NEWSWIRE) – Cancer Genetics, Inc. (Nasdaq: CGIX; “CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced a strategic partnership with Mendel Health, the breakthrough artificial intelligence company focused on using the Mendel.ai deep-learning engine to accelerate and constantly update clinical trial matching for patients.

The companies will be actively working together to integrate Mendel.ai capabilities for clinicians, oncologists, pathologists as well as cancer centers and hospitals with CGI’s disease-focused reports and testing results. The companies expect that initial, early-access partners will be using the system during the second quarter of 2017 with wider rollout through the third and fourth quarter of this year.

“The world’s best cancer treatments are currently in trials, but that doesn’t assure that the patients that fit those trials are aware of their existence even after identifying an actionable biomarker. Traditional navigation tools are no longer realistic as trials are becoming more selective and treatments are becoming both more complex due to combinations and more targeted,” said Karim Galil, M.D., founder and CEO of Mendel Health. “By integrating Mendel’s proprietary AI technology, CGI is the first diagnostic company able to augment the oncologist’s decision making by continuously matching the patient’s data with emerging clinical trials – based on previous diagnostic tests and any shared clinical data or records. CGI’s clinical customers and the patients they serve today are able to make the most out of treatments being developed today, and not decades ago.”

Panna Sharma, CGI’s CEO and President, commented, “Changing patient outcomes can be significantly increased by allowing more patients and cancer care facilities access to artificial intelligence and deep-learning technologies such as Mendel.ai. Improving visibility, providing constant, machine-augmented matching and accelerating access to the vast innovation in biotechnology and pharma trials is needed to raise survival curves and decrease the costs of cancer care. By incorporating our state-of-the art genomic and biomarker reports and data with the ability to integrate real-time clinical trial matching and available health information, we can change patient lives, change outcome curves at cancer centers and improve the major gaps in oncology patient recruitment.”

According to the National Cancer Institute less than 5% of patients with cancer participate in clinical trialsResearch!America, the largest not-for-profit public education and advocacy alliance committed to making research to improve health, found in a national survey of over 1,000 patients that less than 7 of 10 health care providers talk about clinical trials or research, while only 54% of patients believe that the care they are receiving is based on the best or most recent advancements from research.

“Emerging therapies, our knowledge of cancer, and biomarker driven insights are advancing extremely rapidly, and require a constant and vigilant technology-enabled approach to ensure that the best possible insights are made available to our patients and families,” continued Mr. Sharma, “Artificial intelligence has advanced and impacted nearly every industry, and we believe it has the promise to transform laboratory based medicine. In an era where there is tremendous need to advance the innovative new therapies in unfilled trials with precisely matched patients that meet these increasingly complex enrollment criteria, Mendel.ai offers a timely, high-impact and ready-to deploy solution that we believe will make CGI more valuable to our customers and drive value for our shareholders.”

About Mendel.ai & Mendel Health

Mendel.ai is the breakthrough artificial intelligence engine and technology powering Mendel Health. Mendel Health is a for-profit corporation headquartered in San Francisco, CA that rapidly finds optimal matches between cancer patient populations and clinical trials. Mendel uses deep learning technology to sift through unstructured data in medical literature as well as patient health records, in order to suggest evidence-based treatment options and to continuously update the results whenever a new matching trial emerges. Please visit www.mendel.ai for more information about the company and technology.


ABOUT CANCER GENETICS
Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow CGI at:
Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics

 

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.’s expectations regarding the completion, timing, pricing and size of the offering described in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2015 and the Form 10-Q for the Quarter ended March 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.